What is Leerink Partnrs’ Forecast for KYTX FY2024 Earnings?

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Analysts at Leerink Partnrs upped their FY2024 earnings estimates for Kyverna Therapeutics in a report released on Wednesday, November 13th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings of ($3.33) per share for the year, up from their previous forecast of ($3.54). The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.31) per share. Leerink Partnrs also issued estimates for Kyverna Therapeutics’ Q4 2024 earnings at ($0.87) EPS, FY2025 earnings at ($4.35) EPS, FY2026 earnings at ($4.73) EPS, FY2027 earnings at ($5.68) EPS and FY2028 earnings at ($6.03) EPS.

KYTX has been the subject of several other research reports. Wells Fargo & Company lowered their price objective on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday. JPMorgan Chase & Co. dropped their price objective on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. HC Wainwright restated a “neutral” rating and issued a $7.00 price objective on shares of Kyverna Therapeutics in a report on Thursday, September 19th. Rodman & Renshaw initiated coverage on shares of Kyverna Therapeutics in a report on Wednesday, October 9th. They set a “buy” rating and a $16.00 target price for the company. Finally, RODMAN&RENSHAW upgraded Kyverna Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 9th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $25.86.

Kyverna Therapeutics Stock Performance

NASDAQ KYTX opened at $4.35 on Monday. The stock’s 50 day moving average is $5.46 and its 200 day moving average is $8.48. Kyverna Therapeutics has a twelve month low of $4.30 and a twelve month high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings data on Wednesday, November 13th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.01. The firm had revenue of $0.01 million for the quarter.

Hedge Funds Weigh In On Kyverna Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KYTX. FMR LLC purchased a new position in shares of Kyverna Therapeutics in the third quarter worth $33,000. Creative Planning bought a new stake in Kyverna Therapeutics in the 3rd quarter worth about $54,000. Jacobs Levy Equity Management Inc. purchased a new position in Kyverna Therapeutics in the 3rd quarter worth about $97,000. Federated Hermes Inc. bought a new position in Kyverna Therapeutics during the 2nd quarter valued at about $120,000. Finally, BNP Paribas Financial Markets lifted its stake in Kyverna Therapeutics by 2,166.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 27,197 shares of the company’s stock valued at $133,000 after acquiring an additional 25,997 shares during the period. 18.08% of the stock is owned by institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.